Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first three months and full year of 2022. For the quarter, the company expects Core revenues of ¥268,639 million, Core operating profit of ¥98,946 million, Core net income of ¥70,595 million and Core earnings per share of ¥42.91.

For the full year, the company expects Core revenues of ¥1,150,000 million, Core operating profit of ¥440,000 million, Core net income of ¥312,500 million and Core earnings per share of ¥190.00.